By Deena Beasley and Julie Steenhuysen SAN DIEGO, Dec 3 (Reuters) - Details from two large trials of Novo Nordisk's GLP-1 ...
While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, ...
By Deena Beasley SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in ...
The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...
Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing trials last month.
LONDON () -Novo Nordisk shares rose 5% on Wednesday after analysts said that U. price cuts for the Danish drugmaker's ...
Pharma major Novo Nordisk's stock plummeted a record 12.4% on 24 November after the Danish company's weight-loss pill Ozempic ...
Dec 2 (Reuters) - Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback